Copyright: ©Author(s) 2026.
World J Transl Med. Nov 28, 2026; 12(4): 126295
Published online Nov 28, 2026. doi: 10.5528/wjtm.126295
Published online Nov 28, 2026. doi: 10.5528/wjtm.126295
Figure 1 Preferred reporting items for systematic reviews and meta-analyses 2020 flow chart.
The included studies evaluated transcriptomic and proteomic prognostic biomarkers and related clinical trials in pancreatic ductal adenocarcinoma. PDAC: Pancreatic ductal adenocarcinoma; AI: Artificial intelligence.
- Citation: Tarara V, Panteris E, Varlamis S, Andreadou E, Pessach I, Bobos M, Chatzidimitriou M, Mitka S, Papoutsi A, Eleftheriou P, Skepastianos P, Karamitrousis E. Prognostic biomarkers for pancreatic ductal adenocarcinoma: A contemporary systematic review and modelling study. World J Transl Med 2026; 12(4): 126295
- URL: https://www.wjgnet.com/2220-6132/full/v12/i4/126295.htm
- DOI: https://dx.doi.org/10.5528/wjtm.126295